Accessibility Menu
Prelude Therapeutics logo

Prelude Therapeutics(NASDAQ) PRLD

Current Price$3.94
Market Cap$321.77MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2020)-85%
5 Year-86%
1 Year+380%
1 Month-6%
Prelude Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 4.042026-07-21
Prelude Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-7.97%USD 4.392026-07-14
1 month-6.48%USD 4.322026-06-18
3 month-6.26%USD 4.312026-04-22
Year to date+39.31%USD 2.902025-12-31
1 year+379.75%USD 0.842025-07-21
3 year-11.6%USD 4.572023-07-21
5 year-86.19%USD 29.262021-07-22
Since inception-84.58%USD 26.202020-09-25

Prelude Therapeutics Financials at a Glance

Market Cap

$321.77MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$16.72M

Net Income (TTM)

-$77.80M

EPS (TTM)

-$1.06

P/E Ratio

-3.82

Dividend

$0.00

Beta (Volatility)

1.58 (High)

Price

$3.94

Volume

3,376

Open

$4.08

Previous Close

$4.04

Daily Range

$3.90 - $4.08

52-Week Range

$0.75 - $5.69

Estimated Earnings Date

Aug 13, 2026

PRLD News

Foolcom-Featured.png

Prelude Cuts Q2 Losses and Costs 13%

Motley Fool Markets TeamAug 14, 2025

PRLD: Motley Fool Moneyball Superscore

58

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Prelude Therapeutics

Prelude Therapeutics makes new types of cancer medicine. They find specific biological targets to help patients with few treatment options. Their goal is to create smarter and more effective therapies.

Fighting Cancer with Precision

  • JAK2V617F Inhibitors: Medicines designed to target mutations responsible for blood cancers like myelofibrosis; includes lead candidate PRT12396.
  • KAT6 Selective Degraders: Molecules that break down specific proteins to stop the growth of advanced breast cancer and other tumors.
  • Precision Antibody Drug Conjugates: Treatments that combine antibodies with protein-degrading molecules to target tumors with high precision.
  • SMARCA2 and CDK9 Degraders: Therapeutic candidates that use protein degradation to combat various cancer types.

Teaming Up for Growth

  • Signed an exclusive option agreement with Incyte Corporation in November 2025 for the JAK2V617F program.
  • Expanded a research partnership with AbCellera Biologics in October 2025 to develop new antibody-drug conjugates.
  • Received $6.5 million in the third quarter of 2025 from AbCellera Biologics after amending an existing collaboration deal.
  • Decided to focus resources on lead programs in November 2025 by pausing the SMARCA2 development project.

What Makes Prelude Stand Out?

The company uses a specialized discovery engine to create new chemical entities entirely in-house. They focus on targeted protein degradation, which removes disease-causing proteins rather than just blocking them.

The Financial Scorecard

  • Revenue reached $5.6 million in Q4 2025, up 41% from $4 million in Q4 2024.
  • Operating income was -$17.3 million in Q4 2025, which narrowed from a loss of $33.8 million in Q4 2024.
  • Net loss improved to $16.5 million in Q4 2025, compared to a $28.7 million loss in Q4 2024.
  • Operating cash flow turned positive at $23.1 million in Q4 2025, up from -$20.7 million in Q4 2024.

Evolution and Future Focus

Prelude is evolving from an early discovery firm into a clinical-stage business with significant industry partnerships. Its shift toward lead candidates and protein degradation highlights a focus on high-need oncology markets.

AI Generated • May 6, 2026

Industry

Biotechnology

Sector

Health Care

Employees

79

CEO

Krishna Vaddi, PhD

Website

www.preludetx.com

Headquarters

Wilmington, DE 19803, US

PRLD Financials

Key Financial Metrics (TTM)

Gross Margin

97.66%

Operating Margin

-503.21%

Net Income Margin

-465.30%

Return on Equity

-118.24%

Return on Capital

-120.99%

Return on Assets

-65.03%

Earnings Yield

-26.18%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$321.77MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

79.65M

Volume

3.38K

Avg. Volume

459.33K

Financials (TTM)

Gross Profit

$16.33M

Operating Income

-$84.14M

EBITDA

-$76.13M

Operating Cash Flow

-$43.76M

Capital Expenditure

-$20.00K

Free Cash Flow

-$43.78M

Cash & ST Invst.

$81.55M

Total Debt

$17.72M

Prelude Therapeutics Performance Analysis

Prelude Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 7,000,000N/A
20252025-12-31USD 12,140,00073.4%
Prelude Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31-13.2%
Q12026-03-31-18.8%
Prelude Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -2.443.9%
20232023-12-31USD -2.02-17.2%
20242024-12-31USD -1.68-16.9%
20252025-12-31USD -1.29-22.9%
Prelude Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-302.4%
Q32025-09-3036.6%
Q42025-12-31N/A
Q12026-03-3150.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$4.58M

N/A

Gross Profit

$4.19M

N/A

Gross Margin

91.46%

N/A

Market Cap

$321.77MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$4.07M

N/A

Employees

79

N/A

Net Income

-$10.39M

+67.6%

EBITDA

-$9.99M

+68.4%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$81.55M

-17.7%

Total Debt

$17.72M

-1.1%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$14.96M

-2.0%

Short Term Debt

$2.76M

+4.1%

Return on Assets

-65.03%

N/A

Return on Invested Capital

-1.08%

N/A

Free Cash Flow

-$21.69M

+36.7%

Operating Cash Flow

-$21.69M

+36.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ENTAEnanta Pharmaceuticals, Inc.
$13.36-0.41%
FHTXFoghorn Therapeutics Inc.
$5.14-0.39%
IVAInventiva S.A.
$4.54+1.23%
OBIOOrchestra BioMed Holdings, Inc.
$3.63-1.76%

Trending Stocks

Symbol / CompanyPricePrice Chg
ZCMDZhongchao
$5.54+2.77%
SOFISoFi Technologies
$17.16-0.03%
TET1 Energy Inc.
$6.12+0.00%
MARAMara Holdings
$12.50+0.02%

Questions About PRLD

What is the current price of Prelude Therapeutics?

Prelude Therapeutics is trading at $3.94 per share.

What is the 52-week range for Prelude Therapeutics?

Over the past 52 weeks, Prelude Therapeutics has traded between $0.75 and $5.69.

How much debt does Prelude Therapeutics have?

As of the most recent reporting period, Prelude Therapeutics reported total debt of $17.72M.

How much cash does Prelude Therapeutics have on hand?

Prelude Therapeutics reported $21.76M in cash and cash equivalents in its most recent financial results.

What is Prelude Therapeutics’s dividend yield?

Prelude Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services